

Navigating the OTC Analgesic Aisle: What a Pain in the Aspirin!

Laura Meyer-Junco, PharmD, BCPS, CPE University of Illinois Chicago (UIC) College of Pharmacy—Rockford

Disclosure

Nothing to disclose

Painweek.

2


Learning Objectives

At the completion of this presentation, participants should be able to:

- Identify available nonprescription products marketed for pain relief, including their dosage, formulations, indications, and safety and efficacy considerations
- Describe the place of various nonprescription analgesics in the treatment of common painful conditions
- Summarize how to prepare patients to navigate the OTC analgesic aisle on their own

Painweek.





5


Patient Education on Nonprescription Analgesics

- https://www.knowyourdose.org/common-medicines/how-to-read-your-medicine-label/
- https://www.fda.gov/drugs/understanding-over-counter-medicines/educationalresources-understanding-over-counter-medicine.
- https://www.fda.gov/drugs/drug-information-consumers/otc-drug-facts-label
- https://www.getreliefresponsibly.com/pain-medicine-safety



Painweek.

Acetaminophen	
OTC Systemic Analgesics: the Major Players	
Painweek	
_	
7	
A cotominant on Draffle	1
Pharmacologic category: analgesic and antipyretic	-
Nonprescription indications; mild to moderate pain and fever Mechanism of Action; central inhibition of prostaglandin synthesis	
As a result, lacks anti-inflammatory properties and not associated with platelet	
inhibition and gastric side effects	
"APAP (acetaminophen/paracetamol), which has long been regarded as a mainstay of OA treatment, was not recommended by the majority of the Voting Panel for any OA phenotype or comorbidity subgroup." —2019 Osteoarthritis Research Society International (OARSI) Osteoarthritis Guidelines	
"The 2007 review concluded that acetaminophen was effective for acute low back painHowever, this update	
included a placebo-controlled RCT in patients with low back pain that showed no difference in effectiveness between acetaminophen and placebo* —2017 American College of Physicians Low Back Pain Guideline	
BUT it may be helpful in combination with NSAIDs in certain settings and even NSAID-sparingSTAY TUNED!	
PatinWeek Ann Intern Med. 2017;165:514-530. Detecentivities and Cartilipe. 2019;27:1578-1589. Krinsky et al., eds. Annabook of Norprescription Unique 20 de Washington, Co. Chemician Pharmacolicyy distabase. Pharmacolicy distabase.	
8	
	1
Acetaminophen Pharmacokinetic Profile	
Pharmacokinetics: -Rapidly absorbed from the GI tract	
-Extensive hepatic metabolism to inactive glucuronic and sulfuric acid conjugates	
-Small amount of drug metabolized by CYP2E1 to hepatotoxic metabolite, N-acetyl-p-benzoquinoneimine (NAPQI)	
Rapidly detoxified by glutathione at therapeutic doses Supratherapeutic or repeated therapeutic doses of acetaminophen, fasting, and	
alcoholism may deplete glutathione stores, resulting in increased concentrations of NAPQI and hepatotoxicity.	
-CYP2E1 substrate (inducers: ethanol and isoniazid) -Renally excreted as the glucuronide conjugate (40% to 65%) and sulfate metabolite	
(25% to 35%).	
PainWeek. Acetaminophen. Clinical Pharmacology database. Kinnsky et al., dxt. Handbook of Nonprescription Drags. 19th et. Waterhington, DC. American Pharmacol Association, 2018.	









Potentially hepatotoxic in doses > 4 g/d, particularly with chronic use Conservative dosing (≤ 2 g/d) or avoidance Liver disease Concurrent hepatotoxic medication use Poor nutritional intake ≥ 3 alcoholic drinks per day 1 drink = 12 cunces beer, 5 cunces wine, 1.5 cunces of tipuor of tipuor Rare but serious skin reactions Korsky et al. eds. Handbook of Nooprescription Dougs 10 feet Waterington. Oth. Hendison (2016) Korsky et al. eds. Handbook of Nooprescription Dougs 10 feet Waterington. Oth. 650 mg ER product 650 mg ER product

13


Painweek.





14



	-
NSAIDs and Salicylates	
OTC Systemic Analgesics: the Major Players	
Painweek.	
16	
	1
Nonselective NSAIDs Profile	
FDA-approved nonprescription NSAIDs: Ibuprofen (Motrin, Advil), naproxen (Aleve), ketoprofen (not commercially available) - Plus in combination products galare!	
NSAID class: Propionic acids (phenyl-propionic acid)	
Pharmacologic category: analgesic, antipyretic, and anti-inflammatory	
 Nonprescription indications; fever and minor pain associated with arthritis, muscle ache, backache, toothache, headache, common cold, and menstrual cramps 	
Mechanism of action; central and peripheral inhibition of prostaglandin synthesis	
- Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes	
Pharmacokinetics: Rapidly absorbed from the GI tract	
Highly protein-bound (>90%) Extensive hepatic metabolism (primarily glucuronidation) to inactive metabolites	
– CYP2C9 substrate (inhibitors: fluconazole, amiodarone) – Excreted in urine	
Lange Top 100 Nonprescription Drugs. 2018-2019. Lange Top 100 Nonprescription Drugs. 2018-2019. Krinsky et al. eds. Handbook of Nonprescription Drugs. 19 th Buyurofen. Clinical Pharmacology database. Washington, DC: American Pharmacist Association, 2018.	
Bugineri. Giricar Pharmacology Galabase. ************************************	J
17	
A !!	1
Salicylates Profile	
Nonorescription members: Aspirin/acety/salicylic acid (Bayer, Ecotrin, St. Joseph),	
Aspinn'acetylsalicylic acid (bayer, Ecotrin, St. Joseph), Nonacetylated salicylates: magnesium salicylate (Doan's, Percogesic), sodium salicylate (Cystex)	
Pharmacologic category: analgesic, antipyretic, and anti-inflammatory	
Nonprescription indications: fever and minor pain associated with backache, headache, arthritis, and muscle ache; prevention of cardiovascular events	
<u>Mechanism of action</u> : primarily peripheral inhibition of prostaglandin synthesis, and possibly a central mechanism. Aspirin irreversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes	
Pharmacokinetics:	
 Passive absorption of non-ionized drug through the GI tract Affected by dosage form, dissolution time, gastric pH, acid-suppressive drugs, gastric emptying, and food 	
Once absorbed, aspirin is hydrolyzed to salicylic acid and widely distributed to all tissues Salicylic acid is highly protein bound (and concentration dependent, decreasing protein binding at higher concentrations) Hepatic metabolism (primarily conjugation)	
Hepatic metabolism (primarily conjugation) Largely eliminated through kidneys (half-life 2-3 hours for single low dose; 12 hours for anti-inflammatory doses)	
De Maria de la companya della companya della companya de la companya de la companya della compan	













	ALEVE EAST AND SELECTION OF THE PROPERTY OF TH			
N S	aproxen odium			
			www.cvs.com/shop/ad Drug Design, Develop	m Pract 2018;67(8 suppl):S67-S72 tvil-liqui-gels-200mo-prodid-104016 pment and Therapy 2017:11 135-1- Clinical Pharmacology database.

Why discuss "time to peak"?

- Formulation matters for acute pain
- Speed of absorption provides more rapid relief but also better overall pain relief
 Earlier pain reduction associated with longer pain relief and less use of additional analgesics
 Elimination from synovial fluid and blister fluid slower than elimination from plasma
- Fasting acting formulations perform well in studies of acute pain –Addition of caffeine may also speed up absorption
- -Lower doses can be used (solubilized ibuprofen 200 mg = or better than standard ibuprofen 400 mg)
- Taking with food does not affect overall bioavailability but delays absorption and Tmax and reduces Cmax
 - —Of greater consequence for analgesics with Tmax (time to peak) < 2 hours (aspirin, ibuprofen, naproxen sodium, acetaminophen) and less for naproxen (prescription-only) as time to peak is 2-4 hours.</p>

Painweek.

26


Food and Drug Administration CFR Title 21 §201.326

Over-the-counter drug products containing internal analgesic/antipyretic active ingredients; required warnings and other labeling

The following pertains to: "Nonsteroidal anti-inflammatory analgesic/antipyretic active ingredients--including, but not limited to, aspirin, carbaspirin calcium, choline salicylate, ibuprofen, ketoprofen, magnesium salicylate, naproxen sodium, and sodium salicylate."


(A) The stomach bleeding warning states "Stomach bleeding warning [heading in bold type]: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you [bullet] are age 60 or older [bullet] have had stomach ulcers or bleeding problems [bullet] take a blood thinning (anticoagulant) or steroid drug [bullet] take other drugs containing prescription or nonprescription NSAIDs (aspirin, ibuprofen, naproxen, or others) [bullet] have 3 or more alcoholic drinks every day while using this product [bullet] take more or for a longer time than directed".


Painweek.




NSAIDs — Boxed Warnings Prescription Label Prescription Label Prescription Label August 1		Cardiovascular Risk
Gestrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elberly patients are at greater risk for serious gastrointestinal events (see		cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fattal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS). •MOTRIN tablets are contraindicated for treatment of peri- operative pain in the setting of coronary artery bypass
	safety-communication-fda-strengthens-warning-non-aspirin-	Gastrointestinal Risk *NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestinses, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see


Nechanisms of Aspirin/NSAID Induced GI Injury/Bleed Local irritation Low pH of gastric contents (pH 1-3 when fasted) + low pKa of drug = NSAID/ASA phospholipid interaction and permeation into the gastric epithelium The lower the pKa of the NSAID, the greater the "topical toxicity" Aspirin pKa 3.5 Naproxen pKa 4.15 Ibuprofen pKa 5.2 Inhibition of cyclooxygenase and reduction in production of prostaglandins responsible for inhibiting acid secretion by the stomach and promoting the secretion of cytoprotective mucus Impaired of platelet aggregation (increased bleeding tendency)—aspirin pKa = logar/filmic transformed acid dissociation constant. Castromotology 2018;15:500-514 Loaret 1908; 348:1413-1416









	ST. JOSEPH ST. JOSEPH GREVALE ST. JOSEPH JOS			
=	BAYER Ecotrin			
our doctor. Because ast relief of headach	of minor aches and pains or as recommend of its delayed action, this product will no es or other symptoms needing immediate other uses for Bayer Safety Coated 325 mg.	t provide relief.		







Do these strategies reduce topical toxicity?

- Endoscopic studies in healthy, younger adults demonstrate reduced gastric irritation and micro-bleeding compared to plain aspirin

- bleeding/compared to plain aspirin or source to electrical process of the control of the control
- Taking nonenteric coated aspirin with food


 —Lack of data (Journal of Pharmacy and Pharmacology 2012; 64: 465-4


Painweek.

38

Aspirin Formulation	Dose	Frequency	Relative Risk of UGIB	Relative Risk of Gastric Bleed	Relative Risk o Duodenal Bleed
		Regular Overall	4.1 (3.0-5.5)		
Plain	≤325 mg/day	Regular	2.6 (1.7-4.0)	2.6 (1.5-4.3)	2.4 (1.2-4.6)
	>325 mg/day	Regular	5.8 (3.9-8.6)	5.7 (3.6-8.9)	5.1 (2.9-8.9)
		Occasional	1.8 (1.3-2.5)		
		Regular Overall	2.3 (1.3-4.3)		
Enteric	≤325 mg/day	Regular	2.7 (1.4-5.3)	3.2 (1.5-7.0)	2.6 (1.0-7.0)
Coated	>325 mg/day	Regular	Insufficient data		
		Occasional	Insufficient data	-	
		Regular Overall	4.9 (2.6-9.0)		
Buffered	≤325 mg/day	Regular	3.1 (1.3-7.6)	3.6 (1.3-9.8)	2.6 (0.7-9.9)
	>325 mg/day	Regular	7.0 (3.0-16)	7.8 (3-20)	7.0 (2.2-22)
		Occasional	2.2 (1.3-3.9)		

Regular = at least every other day x 1 week





The Side Kick: Caffeine

^-	44~	inα	D.	_f:	۱.
ı :a	TTO	ınα	νr	ATI.	

• OTC products containing caffeine, may also contain:

- AcetaminophenAspirin
- Acetaminophen + aspirin

Caffeine dose range in OTC products per unit: 32 mg-65 mg

- Proposed mechanism of action;
 Improved drug absorption by increased gastric blood flow and lower gastric pH
 Reduced hepatic blood flow resulting in reduced drug metabolism
 Direct effect from blocking central adenosine receptors that influence pain signaling or from blockade of peripheral adenosine receptors in sensory afferents.
 Inhibiting cyclooxygenase (COX) activity at some sites
 Changes in perception of pain as result of changes in mood/emotional state

	_					
		•	ΛΛ	2		1
12	- 1	Ν.	Vν	Æ	◡	Κ.

43

OTC Analgesic Plus Caffeine vs Analgesic Alone

No. studies (No. of participants)	Proportion of patients with at least 50% of max pain relief		NNT
	+ caffeine*	- caffeine	
16 (4262)	48%	41%	14
10 (2139)	60%	51%	10
5 (1503)	33%	25%	13
1 (620)	43%	39%	
8 (2186)	62%	54%	14
4 (707)	46%	32%	7.2
1 (134)	26%	25%	
1 (980)	89%	77%	8
	(No. of participants) 16 (4262) 10 (2139) 5 (1503) 1 (620) 8 (2186) 4 (707) 1 (134)	(No. of participants) + caffeine* 16 (4262)	No. of participants least 50% of max pain relief participants + caffeine* - caffeine

44


Caffeine Beverage Refresher

- ■Coffee (100 to 150 mg caffeine per mug)
- ■Tea (75 mg caffeine per mug)
- Cola/soda/pop drinks (up to 40 mg caffeine per can)
- Energy drinks (~80 mg caffeine per can)
- Plain chocolate (up to 50 mg caffeine per bar)
- Caffeine tablets (100 mg caffeine per tablet)




Painweek.

	BAYER +			
	BACK & BODY EXTRA STRENGTH AND THE CONTROL OF PRINT SOO ENG 100 coales can at			
	ANACIN. Burst Male has heart four the heart at 18 Burst Male has heart four the heart at 18 Burst Male has heart four the heart at 18 Burst Male has heart four the heart at 18 Burst Male has heart four the heart			
ainwee				







OTC Systemic Analgesics: Efficacy
O 10 Systemic Analgesics. Emicacy
PETNIMEEK.

50

Nonprescription Efficacy for Acute Pain* Review of all Cochrane reviews of RCTs of single dose oral analgesics for acute post operative pain (including dental pain, inpatient surgery, and day surgery) in adult patients Number needed to treat (NNT) for at least 50% pain relief over four to six hours following a single dose Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews (Review) Moore RA, Wiffen PJ, Derry S, Maguire T, Roy YM, Tyrrell L Cochrane Database Syst Rev 2015 Nov 4;(11):CDD10794

*Excludes migraine pain, headache, and menstrual pain

51

Painweek.

Studied Drug	Associated Product (s)	Dose (mg)	NNT (95% CI)
Ibuprofen + Acetaminophen	Regular release 200 mg ibuprofen and	400 + 1000	1.5 (1.4 to 1.7)
Ibuprofen + Acetaminophen	Tylenol extra strength 500 mg tab/caplets	200 + 500	1.6 (1.5 to 1.8)
Ibuprofen Fast Acting	Advil liquid-gels	400	2.1 (1.9 to 2.3)
Ibuprofen Fast Acting	Advil Migraine (solubilized ibuprofen)	200	2.1 (1.9 to 2.4)
Ibuprofen + Caffeine	Combination product not available in US	200 + 100	2.I (I.9 to 3.I) [NNH I9]
Ibuprofen	Advil 400 mg tablet/caplet	400	2.5 (2.4 to 2.6)
Naproxen	Aleve liquid gels, tab/caplets	440	2.7 (2.2 to 3.5)
Ibuprofen	Advil 200 mg tablet	200	2.9 (2.7 to 3.2)
Naproxen	Aleve liquid gels, tab/caplets	220	3.4 (2.4 to 5.8)
Acetaminophen	Tylenol extra strength 500 mg tab/caplets	500	3.5 (2.7 to 3.5)
Acetaminophen	500 mg or 325 mg (regular strength) tab/caplets	975-1000	3.6 (3.2 to 4.1)
Aspirin	Regular strength 325 mg tablet and enteric coated	650	4.2 (3.8 to 4.6)
Aspirin	Bayer Extra Strength 500 mg coated caplets	1000	4.2 (3.8 to 4.6) [NNH 7.5]
Acetaminophen	Tylenol Arthritis/8 hour (extended release)	650	4.6 (3.9 to 5.5)
Aspirin	Bayer Extra Strength 500 mg coated caplets	500	Not better than placebo

Higher or Lower Doses in Acute Pain? Direct Comparison Studies










US Food and Drug Administration. 3882B1 13 McNeil-Acetaminophen. www.scr cm/document/1087288/US Food-and-Drug-Administration-3882B1-13-McNeilAcetaminophen. Pain 2012; 153: 1384–1367 Br J Clin Pharmacol 2007 Mar;63(3):271-8.


53


OTC Topical Analgesics












of muscles and j	or "the temporary relie pints." the skin, produce a lo		•
	ct from pain at the site		
Group A	Group B	Group C	Group D
Rubefacients Redness/warm due to vasodilation Methyl Salicylate	Produce cooling sensation Menthol Camphor	Cause vasodilation Histamine dihydrochloride [Methyl nicotinate]	TRPVI agonists Substance P Depletors Capsaicin < 1% Capsicum





Efficacy Outcome	No. studies (No. of participants)	Proportion o 50% pa	NNT	
Topical Salicylates* [Cochrane Review]		Drug	Placebo	
Acute pain	4 (324)	64% (25%-	34% (0%-59%)	3.2
strains, sprains, acute low back pain)	[low quality evidence]	95%) at 7 days	at 7 days	
Chronic pain	6 (455)	45% (38%-	28% (17%- 38%)	6.2
osteoarthritis, bursitis, back pain)	[low quality evidence]	80%) at 14 days	at 14 days	
Safety Outcome	No. studies	Drug	Placebo	NNH
Topical Salicylates				
All adverse events (acute + chronic pain)	11	15% (0%-83%)	9% (0%-52%)	17
Local adverse events (acute + chronic pain)	10	6% (0%-24%)	2% (0%-9%)	31
Methyl salicylate 10%, menthol 3% patch	4	6.7%	5.8%	



FDA Safety Communication

- Issued in 2012 regarding rare cases of burns with OTC topical products
- In many cases, burns occurred after one application
- Majority of cases with higher concentration menthol as the single ingredient or combination products containing both menthol (>3%) and methyl salicylate (>10%)

FDA Recommendations to Consumers Regarding Topical OTC Products FDA Recommendations to Consumers Regarding Topical OTC Products:

1 you experience pain, swelling, or bilstering of the skin, stop using the product and seek medical attention immediately. These products should not cause pain or skin damage. These products produce local warmth or coolines.


-Do not abplay the area tightly and do not apply local heat (heating pads, lamps, hot water in bags or bottles) because doing so can increase the risk of serious burns.


-Do not apply to wounds or damaged, broken, or irritated skin. Also do not allow contact with eyes and mucous membranes (such as the skin inside your nose, mouth, or genitals).


-Talk to a health care professional if you have any questions or concerns about using OTC topical muscle and joint pain relievers.

Painweek.


65







Efficacy Outcome	No. studies (No. of participants)	Proportion of patients with spain relief			
Topical Capsaicin 0.025-0.075%					
Neuropathic pain (0.075%)	4 (313)	57% (53%-75%) at 4 weeks	42% (31%-55%) at 4 weeks	6.4	
Musculoskeletal pain (0.025%)	3 (368)	38% (34%-42%) at 4 weeks	25% (17%-37%) at 4 weeks	8.1	
Safety Outcome	No. studies	Drug	Placebo	NNH	
Topical Capsaicin 0.075% [Cochrane Review]					
Local skin reaction (over 6-8 weeks of therapy)	6	63% (31% - 93%)	24% (9%-40%)	2.5	
Topical Capsaicin 0.025%					
Local adverse effect at 4 weeks	3	49%	10%	2.6	
OARSI 2019 guidelines: recommend against ca ACR 2019 guidelines: conditionally recommend Arthritis Care & Research. 2020. 72(2 Odecontrinitis and Cartilege 2019; 27:	capsaicin for knee 0:149-162	e osteoarthritis Cochrane Datab	BMJ 2004;328(74 ase of Systematic Reviews 20 03. DOI: 10.1002/14851858.C	14, Issue 11.	



Lidocaine OTC Patches


- Double blind placebo controlled study of 87 patients with back pain or arthritis
- OTC 3.6% lidocaine and 1.25% menthol patch *noninferior* to prescription 5% lidocaine patch
- -Menthol may increase permeability and increase efficient delivery of lidocaine



Painweek.

Pain Manag. 2017;7(6):489-498

71



۱n			

- Reconcile OTC products with patients and frequently -Self-care → clinician-assisted self care
- Educate patients on the risks of OTC polypharmacy and on reading labels
 Avoid the brand extension trap (discuss products in terms of active ingredient instead of brand name)

 For acute pain, oral formulation matters (faster = greater pain relief)

- For GI protection, oral formulation may be less important (drug, dose, duration, and risk factors more important)
 Topical diclofenac is now available OTC and recommended by guidelines for OA OTC topical counterri
- OTC lidocaine patches may be a cheaper alternative to Rx lidocaine patches

Painweek.

73



Navigating the OTC Analgesic Aisle: What a Pain in the Aspirin!

Laura Meyer-Junco, PharmD, BCPS, CPE University of Illinois Chicago (UIC) College of Pharmacy—Rockford